Recurring Mistakes (And Remedies) For Life Sciences M&A
Life science management teams fall victim to recurring mistakes and entrapments. This article discusses avoidable missteps in M&A transactions and their respective remedies.
Recurring Mistakes (And Remedies) For Life Sciences M&A
Published in Life Science Leader, January 2018
Authors: Dr. Oded Ben-Joseph and Thomas Busby
As members of a specialized life sciences investment banking group focused on private equity financing and M&A, we often note that life science management teams fall victim to recurring mistakes and entrapments. Below is a list of avoidable missteps in M&A transactions and their respective remedies.
News
Outcome Capital and YAFO Capital Announce Strategic Partnership to Expand Global Strategic and Financial Services to Biopharma and Healthcare Clients
The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai – September 14, 2023. Outcome Capital, a specialized life science advisory and investment banking firm, and YAFO Capital, a Shanghai-based boutique investment banking and advisory firm, announced that the companies […]
Read MoreResources
Outcome Capital Life Sciences Pulse, August 2023
Outcome Capital Life Science Market Pulse August 2023 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2023. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy
